* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
New Technology Impex LLC (შპს ნიუ ტექნოლოჯი იმპექსი) is a medical face-mask plant built in 2020 for the COVID-19 demand. It was opened on the premises of the Technical University's technical training centre with TBC Bank financing, on a project cost reported at USD 1.8m, running two production lines rated at 12 million masks a month at full capacity and staffed at 20 people with a stated plan to reach 50. Its product was branded Faceguard, made from melt-blown material. The previous text on this record was the sentence "გაიწევა მხოლოდ ძირითადი საქმიანობის საჭიროების ფარგლებში", a fragment of an accounting-policy note that had been captured as a business description; it said nothing about the company. Held 90% by Davit Miminoshvili, who is also director, and 10% by the state Partnership Fund. Files the Category III simplified form. It filed for FY2020 to FY2022 and stopped: FY2022 revenue is ₾0.22m at a 61.7% gross margin, with EBITDA of ₾-0.46m and a net loss of ₾-0.73m on ₾0.28m of total assets. The shape is a pandemic capacity build that did not outlive the demand. The Medical Devices — Production bucket is correct for what it was built to make, but nothing here is evidence that it still operates.
| Ratio | 2020 | 2021 | 2022 |
|---|---|---|---|
| Margins | |||
| Gross Margin | -17.2% | -198.6% | 61.7% |
| EBITDA Margin | -59.1% | -237.2% | -211.7% |
| EBITDAR | -857 | -2,713 | -437 |
| EBITDAR Margin | -56.0% | -232.1% | -202.0% |
| EBIT Margin | -65.0% | -249.2% | -275.2% |
| Net Profit Margin | -97.3% | -253.5% | -335.9% |
| Operating Expense % of Sales | 41.9% | 38.6% | 273.4% |
| Returns | |||
| Return on Assets (ROA) | -28.4% | -189.9% | -256.3% |
| Return on Equity (ROE) | N/A | N/A | N/A |
| ROIC [EBIT / Invested Capital] | -19.6% | -195.5% | -285.2% |
| Leverage & debt balances | |||
| Debt-to-Assets | 124.7% | 363.9% | 1557.4% |
| Debt-to-Equity | -4.73x | -1.36x | -1.05x |
| Debt-to-EBITDA | N/A | N/A | N/A |
| Equity-to-Assets | -26.4% | -268.4% | -1481.1% |
| Net Debt | 6,456 | 5,677 | 4,407 |
| Cash & Equivalents | 79 | 1 | 8 |
| Total Debt | 6,535 | 5,678 | 4,414 |
| Liquidity & working capital | |||
| Current Ratio | 0.60x | 0.08x | 0.04x |
| Quick Ratio | 0.07x | 0.08x | 0.04x |
| Cash Ratio | 0.01x | 0.00x | 0.00x |
| Total Current Assets | 3,971 | 434 | 192 |
| Total Current Liabilities | 6,621 | 5,753 | 4,481 |
| Inventory | 3,540 | N/A | N/A |
| Trade Receivables | 197 | 208 | 9 |
| Trade Payables | 10 | 66 | 62 |
| Net Working Capital | -2,650 | -5,319 | -4,289 |
| Net Working Capital % of Revenue | -173.1% | -455.1% | -1983.4% |
| Trade Working Capital | 3,727 | 142 | -54 |
| Trade Working Capital % of Revenue | 243.5% | 12.2% | -24.8% |
| Change in Trade Working Capital | N/A | -3,585 | -196 |
| Turnover & efficiency | |||
| Inventory Turnover | 0.51x | N/A | N/A |
| Days Inventory Outstanding (DIO) | 720.1 | N/A | N/A |
| Receivables Turnover | 7.76x | 5.61x | 24.67x |
| Days Sales Outstanding (DSO) | 47.0 | 65.1 | 14.8 |
| Payables Turnover | 178.72x | 52.80x | 1.33x |
| Days Payable Outstanding (DPO) | 2.0 | 6.9 | 275.3 |
| Cash Conversion Cycle | 765.1 days | 58.2 days | -260.5 days |
| Asset Turnover | 0.29x | 0.75x | 0.76x |
| Cash flow & dividends | |||
| Operating Cash Flow | -4,808 | 899 | 263 |
| Free Cash Flow (OCF − Capex proxy) | -6,167 | -757 | 267 |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →